Sanofi (SNY) EBIT Margin (2009 - 2026)

Sanofi has disclosed EBIT Margin across 18 years of filings, most recently posting 9.03% for Q2 2026.

• In Q2 2026, EBIT Margin fell 572.0% year-over-year to 9.03%; the TTM figure through Jun 2026 stood at 12.59% (down 784.0% YoY), while the FY2025 annual figure was 14.54%, down 311.0% from the prior year.
• EBIT Margin came in at 9.03% for Q2 2026 at Sanofi, down from 20.18% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 122.84% in Q4 2023 to a low of 8.91% in Q4 2024.
• Average EBIT Margin over 5 years is 26.91%, with a median of 21.0% recorded in 2026.
• Year-over-year, EBIT Margin surged 10543 bps in 2023 and tumbled 11393 bps in 2024.
• Over 5 years, EBIT Margin stood at 17.4% in 2022, then soared by 606 bps to 122.84% in 2023, then sank by 93 bps to 8.91% in 2024, then soared by 527 bps to 55.87% in 2025, then sank by 84 bps to 9.03% in 2026.
• Per Business Quant data, the three most recent EBIT Margin figures were 9.03% in Q2 2026, 20.18% in Q1 2026, and 55.87% in Q4 2025.